France's Clariane H1 revenue rises 4.6% organically, EBITDA margin improves

Clariane SE

29/07/2026 17:03

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
    * France care facility operator's H1 revenue rose 4.6% organically, driven by volume and price gains
    * EBITDA margin improved to 10.4% from 9.5% pro forma, reflecting operational improvements
    * Company completed €1.06 bln in refinancing, extending debt maturities and boosting liquidity

Outlook
    * Clariane confirms average annual organic revenue growth objective of about 5% through 2026
    * Clariane maintains all financial and non-financial objectives for 2026

Result Drivers
    * VOLUME AND PRICE GAINS - Co said revenue growth was supported by a 1.6% increase in volumes and a 3.0% rise in prices
    * OPERATIONAL IMPROVEMENTS - Margin gains and higher EBITDA were attributed to operational measures, including cost control, case mix management, and adaptation to new pricing frameworks
    * PORTFOLIO CHANGES - Revenue and EBITDA were affected by disposals and closures of underperforming facilities, partially offset by new facility openings

Company press release:  ID:nGNE50zf16 
Key Details
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
 H1                  EUR 2.7   EUR 2.70
 Revenue             bln       bln (1
                               Analyst)
 H1 Net              EUR 42     
 Loss                mln       
 Attribut                      
 able To                       
 Group                         
 Pre-IFRS                      
 16                            
 H1                  EUR 563    
 EBITDAR             mln       
 H1                  EUR 280    
 EBITDA              mln       
 H1 Free             EUR 20     
 Cash                mln       
 Flow                          
 Analyst Coverage
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the healthcare facilities & services peer group is "buy"
    * Wall Street's median 12-month price target for Clariane SE is €4.80, about 21% above its July 28 closing price of €3.97
    * The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
    * July 27 - Ensign Group Q2 profit beats on higher occupancy rates
    * July 27 - Welltower raises 2026 FFO forecast on senior housing demand
    * July 28 - Chemed Q2 revenue beats estimates, helped by VITAS segment growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)